- Home
- ESS vs WST Comparison
ESS vs WST Comparison
Compare ESS & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESS
- WST
- Stock Information
- Founded
- ESS 1971
- WST 1923
- Country
- ESS United States
- WST United States
- Employees
- ESS N/A
- WST N/A
- Industry
- ESS Real Estate Investment Trusts
- WST Medical/Dental Instruments
- Sector
- ESS Real Estate
- WST Health Care
- Exchange
- ESS Nasdaq
- WST Nasdaq
- Market Cap
- ESS 17.0B
- WST 18.9B
- IPO Year
- ESS 1994
- WST N/A
- Fundamental
- Price
- ESS $267.28
- WST $253.59
- Analyst Decision
- ESS Hold
- WST Buy
- Analyst Count
- ESS 18
- WST 7
- Target Price
- ESS $299.44
- WST $332.50
- AVG Volume (30 Days)
- ESS 381.9K
- WST 575.5K
- Earning Date
- ESS 10-28-2025
- WST 10-23-2025
- Dividend Yield
- ESS 3.85%
- WST 0.35%
- EPS Growth
- ESS 54.17
- WST N/A
- EPS
- ESS 12.44
- WST 6.68
- Revenue
- ESS $1,887,957,000.00
- WST $2,960,200,000.00
- Revenue This Year
- ESS $3.86
- WST $6.28
- Revenue Next Year
- ESS $3.70
- WST $6.02
- P/E Ratio
- ESS $21.47
- WST $37.92
- Revenue Growth
- ESS 9.79
- WST 2.90
- 52 Week Low
- ESS $243.85
- WST $187.43
- 52 Week High
- ESS $317.73
- WST $352.33
- Technical
- Relative Strength Index (RSI)
- ESS 51.25
- WST 56.31
- Support Level
- ESS $263.00
- WST $249.94
- Resistance Level
- ESS $270.37
- WST $264.06
- Average True Range (ATR)
- ESS 4.46
- WST 5.67
- MACD
- ESS 0.89
- WST 0.67
- Stochastic Oscillator
- ESS 71.33
- WST 53.28
About ESS Essex Property Trust Inc.
Essex Property Trust owns a portfolio of 257 apartment communities with over 62,000 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
About WST West Pharmaceutical Services Inc.
West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs, which include large molecule biologics, peptides such as GLP-1 receptor agonists, and small molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.